Topical Solution for the Treatment of Atopic Dermatitis

Inclusion Criteria: * Male or female aged between 2 and 75 years, inclusive, at the screening visit. 2. AD diagnosis according to the Hanifin/Rajka criteria with one eczema outbreak at the screening and baseline. 3\. Presence of at least two lesional areas. These areas should be at the left and right side of the body and occupying a body surface area (BSA) in each side between 0.1% and 10% of the BSA. IGA score of the two sites not differ by more than 1 point. 4\. Mild to moderate disease severity of AD defined by an IGA score of 2 or 3 at baseline (IGA scale from 0 to 4). 5\. Total BSA of AD involvement ≤ 10% in each side of the body (≤ 20% maximum). 6. Normal weight as defined by a Quetelet Index (Body Mass Index \[BMI\]: weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2 (both included). 7\. General medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial. 8\. Parent's or legal guardian's written informed consent and child assent, if appropriate or patient's inform consent for patients ≥ 18 years of age before any assessment is performed. 9\. Able to communicate with the investigator and comply with the requirements of the study (for children the parent can assist when necessary). Exclusion Criteria: * 1\. Female subject of childbearing potential without use of effective birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period; Note: Estrogen based hormonal contraception may not be reliable when SP14019-F-01 topical solution is applied, therefore to be eligible for this trial, women of childbearing potential should either: 1. use a double barrier method to prevent pregnancy (i.e., using a condom with either diaphragm or cervical cap); 2. use hormonal based contraceptives in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom); 3. use an intrauterine device in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom); 4. be only non-heterosexually active, practice heterosexual abstinence, or have a vasectomized partner (confirmed sterile). Women with tubal ligation are required to use 1 non-hormonal contraceptive method. Women who are postmenopausal for at least 2 years, and women with total hysterectomy are considered of non-childbearing potential. Males with partners of childbearing potential should inform them of their participation in this clinical study and use a highly effective method of birth control during the study. 2\. Pregnant woman or with a positive pregnancy test or breast feeding at baseline. 3\. Any condition in the lesions that in the opinion of the investigator could interfere with clinical assessments, e.g. acne, infection, rash other than AD, sunburn, scars, hairy or tattooed area. 4\. Patients receiving phototherapy or systemic therapy for AD within 4 weeks before the first application of trial medication. 5\. Patients receiving antibiotics, topical therapy for AD within 2 weeks before the first application of trial medication. 6\. Patients taking antihistamines within 1 week before the first application of trial medication. 7\. Patients receiving radiation therapy, systemic therapy with cytostatics or biological therapy within 24 weeks before the first application of trial medication, or with previous history of malignancy (excluding basal cell carcinoma). 8\. Patients with any acute skin infection (superinfection or secondary impetiginisation). 9\. Patients with confirmed hypertension, renal disease or serious infections at screening. 10\. Any currently active allergy such as but not limited to drug allergy, food allergy or hay fever. 11\. Previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the trial medication administered in this trial. 12\. Participation in an investigational drug trial within 30 days prior to the first application of trial medication. 13\. Any condition (including but not limited to alcohol and drug use), which in the opinion of the investigator could compromise the patient safety or compliance with trial procedures. 14\. Subjects who have received or are planning to receive any vaccination within 28 days prior to the first dose of study medication, or planning to receive a vaccination during the course of the study.